Effects of Lipids on the Pathogenesis of Progressive Renal Failure: Role of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in the Prevention of Glomerulosclerosis

Mineral and Electrolyte Metabolism

Volumn 22, Issue 1-3, 1996, Pages 147-152

  Guijarro, Carlos ^a   Keane, William F ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

Glomerulosclerosis; Lipids; Progression; Renal disease

Indexed keywords

COLLAGEN TYPE 4; COLONY STIMULATING FACTOR; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN;

ANIMAL CELL; ANIMAL MODEL; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; GLOMERULOSCLEROSIS; HUMAN; HUMAN CELL; KIDNEY FAILURE; LIPID METABOLISM; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMAL; ANTICHOLESTEREMIC AGENTS; CELL DIVISION; COLLAGEN; COLONY-STIMULATING FACTORS; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION; GLOMERULAR MESANGIUM; GLOMERULONEPHRITIS; HUMAN; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IN VITRO; KIDNEY; KIDNEY FAILURE, CHRONIC; LOVASTATIN; MEVALONIC ACID; SUPPORT, NON-U.S. GOV'T;

EID: 0029655754     PISSN: 03780392     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (45)

1. Virchow R: A more precise account of fatty metamorphosis; in Chance F (ed): Cellular Pathology, ed 2. Gryphonham, Gryphon Editions, 1860; pp 324-366.
2. Attman PO, Alaupovic P: Lipid abnormalities in chronic renal insufficiency. Kidney Int 1991;31(suppl):16-23.
3. Kaysen GA: Hyperlipidemia of the nephrotic syndrome. Kidney Int 1991;31(suppl):8-15.
4. Kasiske BL, Umen AJ: Persistent hyperlipidemia in renal transplant patients. Medicine (Baltimore) 1987;66:309-316.
5. Guijarro C, Keane WF: Lipid abnormalities and changes in plasma proteins in glomerular diseases and chronic renal failure. Curr Opin Nephrol Hypertens 1993;2:372-379.
6. Guijarro C, Keane WF: Lipid-induced glomerular injury. Nephron 1994;67:1-6.
7. Moorhead JF: Lipids and the pathogenesis of kidney disease. Am J Kidney Dis 1991;17: 65-70.
8. Norum KR, Gjone E, Glomset JA: Familial lecithin:cholesterol acyltransferase deficiency, including fish eye disease; in Scriver CR, Beaudet al, Sly WS, Valle D (eds): The Metabolic Bases of Inherited Disease, ed 6. New York, McGraw Hill, 1989; pp 1181-1194.
9. Saito T, Sato H, Oikawa S, Kudo K, Kurihara I, Nakayama K, et al: Lipoprotein glomerulopathy. Report of a normolipidemic case and review of the literature. Am J Nephrol 1993; 13:64-68.
10. Lee HS, Lee JS, Koh HI, Ko KW: Intraglomerular lipid deposition in routine biopsies. Clin Nephrol 1991;36:67-75.
11. Sato H, Suzuki S, Kobayashi H, Ogino S, Inomata A, Arakawa M: Immunohistological localization of apolipoproteins in the glomeruli in renal disease: Specifically apo B and apo E. Clin Nephrol 1991;36:127-133.
12. Takemura T, Yoshioka K, Aya N, Murakami K, Matumoto A, Itakura H, et al: Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases. Kidney Int 1993;43: 918-927.
13. Mulec H, Johnson SA, Bjorck S: Relation between serum cholesterol and diabetic nephropathy. Lancet 1990;335:1537-1538.
14. Samuelsson O, Aurell M, Knight-Gibson C, Alaupovic P, Attman PO: Apolipoprotein-B- containing lipoproteins and the progression of renal insufficiency., Nephron 1993;63:279- 285.
15. Rabelink AJ, Hené RJ, Erkelens DW, Joles JA, Koomans HA: Partial remission of nephrotic syndrome in patient on long-term simvastatin (letter). Lancet 1990;335:1045-1046.
16. Chan PC, Robinson JD, Yeung WC, Cheng IK, Yeung HW, Tsang MT: Lovastatin in glomerulonephritis patients with hyperlipidemia and heavy proteinuria. Nephrol Dial Transplant 1992;7:93-99.
17. Kasiske BL, Velosa JA, Halstenson CE, La Belle P, Langendorfer A, Keane WF: The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome. Am J Kidney Dis 1990;15:8-15.
18. Golper TA, Illingworth DR, Morris CD, Bennett WM: Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria. Am J Kidney Dis 1989;13:312-320.
19. Keane WF, Kasiske BL, O'Donnell MP, Kim Y: The role of altered lipid metabolism in the progression of renal disease: experimental evidence. Am J Kidney Dis 1991;17:38-42.
20. Tolins JP, Stone BG, Raij L: Interactions of hypercholesterolemia and hypertension in initiation of glomerular injury. Kidney Int 1992; 41:1254-1261.
21. Kasiske BL, O'Donnel MP, Keane WF: The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 1992;19:I110-I115.
22. Hirano T, Morohoshi T: Treatment of hyperlipidemia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonucleoside nephrosis. Nephron 1992;60:443-447.
23. Diamond JR, Ding G, Frye J, Diamond IP: Glomerular macrophages and the mesangial proliferative response in the experimental nephrotic syndrome. Am J Pathol 1992;141: 887-894.
24. Kasiske BL, O'Donnel MP, Schmitz PG, Kim Y, Keane WF: Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int 1990;37:880-891.
25. Rayner HC, Ward L, Walls J: Cholesterol feeding following unilateral nephrectomy in the rat leads to glomerular hypertrophy. Nephron 1991;57:453-459.
26. Keane WF, Kasiske BL, O'Donnell MP, Schmitz PG: Therapeutic implications of lipid- lowering agents in the progression of renal disease. Am J Med 1989;87:21N-24N.
27. Diamond JR: Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int 1991;31(suppl):29-34.
28. Gröne HJ, Miller B, Walli AK, Eisenhauer T, Gröne E, Seidel D: Amelioration of lipid glomerulopathy by the HMG-CoA reductase inhibitor lovastatin in guinea pigs. An effect without pronounced reduction in plasma cholesterol (abstract). J Am Nephrol 1992;3:739.
29. Kasiske BL, Lee HS, Kim Y, O'Donnell MP, Keane WF: Independent effects of cholesterol and HMG-CoA reductase inhibition on chronic vascular rejection in rats (abstract). J Am Soc Nephrol 1992;3:843.
30. Kauffman RF, Bean JS, Bensch WR: Reduction of intimal thickening by lovastatin in the absence of reduction in serum cholesterol (abstract). FASEB J 1994;8:319.
31. Pesekdiamond I, Ding GH, Frye J, Diamond JR: Macrophages mediate adverse effects of cholesterol feeding in experimental nephrosis. Am J Physiol 1992;263:F776-F783.
32. Satriano JA, Hora K, Shan Z, Stanley ER, Mori T, Schlondorff D: Regulation of monocyte chemoattractant protein-1 and macrophage colony-stimulating factor-1 by IFN-gamma, tumor necrosis factor-alpha, IgG aggregates, and cAMP in mouse mesangial cells. J Immunol 1993;150:1971-1978.
33. Mori T, Bartocci A, Satriano J, Zuckerman A, Stanley R, Santiago A, et al: Mouse mesangial cells produce colony-stimulating factor-1 (CSF-1) and express the CSF-1 receptor. J Immunol 1990;144:4697-4702.
34. Rovin BH, Tan LC: LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int 1993;43:218-225.
35. Wasserman J, Santiago A, Riflci V, Holthofer H, Scharschmidt L, Epstein M, et al: Interactions of low density lipoprotein with rat mesangial cells. Kidney Int 1989;35:1168-1174.
36. Coritsidis G, Rifici V, Gupta S, Rie J, Shan ZH, Neugarten J, et al: Preferential binding of oxidized LDL to rat glomeruil in vivo and cultured mesangial cells in vitro. Kidney Int 1991; 39:858-866.
37. Gröne EF, Abboud HE, Hohne M, Wall AK, Gröne HJ, Stuker D, et al: Actions of lipoproteins in cultured human mesangial cells: Modulation by mitogenic vasoconstrictors. Am J Physiol 1992;263:F686-F696.
38. O'Donnell MP, Kasiske BL, Atluru D, Kim Y, Keane WF: Low density lipoprotein (LDL) potentiates the mitogenic actions of insulin (I) and insulin-like growth factor-1 (IGF-1) in rat mesangial cells (abstract). J Am Soc Nephrol 1992;3:476.
39. Abboud HE: Growth factors and the mesangium. J Am Soc Nephrol 1992;2(suppl): 185- 189.
40. O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF: Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 1993;91: 83-87.
41. Grandaliano G, Biswas P, Choudhury GG, Abboud HE: Simvastatin inhibits PDGF- induced DNA synthesis in human glomerular mesangial cells. Kidnex Int 1993;44:503-508.
42. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 1990;343:425- 430.
43. Keane WF, Kasiske BL, O'Donnell MP, Kim Y: Oxidized low density lipoprotein increases mesangial cell expression of type IV collagen [α1(IV)] m-RNA (abstract). J Am Soc Nephrol 1992;3:635.
44. Kasiske BL, Kim Y, O'Donnell MP, Lee HS, Keane WF: Cholesterol mediated glomerular injury: Influence of age, glomerular macrophages, growth and mesangial matrix (abstract). J Am Soc Nephrol 1991;2:682.
45. Ding GH, Pesekdiamond I, Diamond JR: Cholesterol, macrophages, and gene expression of TGF-beta-1 and fibronectin during nephrosis. Am J Physiol 1993;264:F577-F584.